FDA Approves Label Expansion for Osilodrostat for Cushing's Syndrome

FDA expands Isturisa approval to all endogenous Cushing's forms

The U.S. Food and Drug Administration (FDA) has approved Isturisa (osilodrostat) to treat adults with all forms of endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative. This marks an expansion of the approved indication for Isturisa, which had previously been cleared only for use by adults with Cushing’s disease, a specific subtype of Cushing’s syndrome. The therapy is marketed by Recordati Rare Diseases, whic…

FDA Approves Label Expansion for Osilodrostat for Cushing's Syndrome

The FDA cleared the expanded indication for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.